VINC实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States...

Stats
今日成交量	1.72M
平均成交量	1.18M
市值	15.63M
EPS	$0 ( 2024-03-26 )
下一个收益日期	( $-0.260 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.390
ATR14	$0.0120 (1.65%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-07	Izumi Raquel E.	Buy	123 750	Stock Option (right to buy)
2024-03-07	Seelenberger Alexander A.	Buy	93 750	Stock Option (right to buy)
2024-03-07	Hamdy Ahmed Md	Buy	146 746	Stock Option (right to buy)
2024-03-07	Thomas Tom C	Buy	93 750	Stock Option (right to buy)
2023-08-11	Seelenberger Alexander A.	Buy	10 500	Common Stock

INSIDER POWER
100.00
Last 97 transactions
Buy: 7 261 732 \| Sell: 1 766 942

音量相关性

長: -0.44 (neutral)

短: -0.91 (very strong negative)

Signal:(31.431) Neutral

Vincerx Pharma, Inc. 相关性

10 最正相关
SVAC	0.929
PAIC	0.909
RMRM	0.901
TLGT	0.894
MTSL	0.893
SVOK	0.862
MODV	0.861
CLMT	0.858
BOXL	0.842
ABNB	0.839

10 最负相关
AMRB	-0.955
NETE	-0.938
MMAC	-0.917
RAVN	-0.869
SRAC	-0.86
SBBP	-0.859
LWAC	-0.855
MGPI	-0.841
BOCH	-0.836
SHSP	-0.808

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Vincerx Pharma, Inc. 相关性 - 货币/商品

-0.72
( moderate negative )

-0.71
( moderate negative )

0.00
( neutral )

-0.74
( moderate negative )

0.00
( neutral )

0.02
( neutral )

Vincerx Pharma, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-915 000 (0.00 %)
EPS:	$-1.890

FY	2023
营收:	$0
毛利润:	$-915 000 (0.00 %)
EPS:	$-1.890

FY	2022
营收:	$0
毛利润:	$-939 000 (0.00 %)
EPS:	$-2.72

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-7.48

Financial Reports:

No articles found.

Vincerx Pharma, Inc.

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.